Part one of this article series focused on multiple lines of evidence that suggest therapeutic effects of psychedelics are dependent on the serotonin 2A receptor (5-HT2AR). While it’s well established that 5-HT2AR activation is necessary for the psychedelic experience,1 it’s still up in the air whether the antidepressant and anxiolytic effects that are seen preclinically and clinically are reliant…


Previous articlePharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome
Next articleMindMed Joins Clinical Trials Transformation Initiative